Genetron/GTH

$3.91

-0.26%
-
1D1W1MYTD1YMAX

About Genetron

Genetron Holdings Limited is a precision oncology company that specializes in cancer molecular profiling and harnesses technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive product and service portfolio that cover the full-cycle of cancer care from early screening, to diagnosis and treatment recommendations, to continuous monitoring and continuous care. The Company operates its businesses primarily within the China market.

Ticker

GTH

Sector

Healthcare

Trading on

NASDAQ

Industry

Healthcare Facilities

CEO

Sizhen Wang

Employees

799

Headquarters

Beijing, China

Genetron Metrics

BasicAdvanced
$124.27M
Market cap
-
P/E ratio
-$10.90
EPS
0.50
Beta
-
Dividend rate

Genetron Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-124.23% profit margin
QuarterlyAnnual
Q4 22
QoQ growth
Revenue
¥650.7M
372.55%
Net income
¥-808.4M
243.71%
Profit margin
-124.23%
-27.27%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

Buy or sell Genetron stock

Buy or sell Genetron stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing